Clinical and Molecular Profiling of AML Patients With Chromosome 7 or 7q Deletions in the Context of TP53 Alterations and Venetoclax Treatment

Authors

Hussein A Abbas
Edward Ayoub
Hanxiao Sun
Rashmi Kanagal-Shamanna
Nicholas J Short
Ghayas Issa
Musa Yilmaz
Sherry Pierce
Daniel Rivera
Brent Cham
Shane Wing
Ziyi Li
Danielle Hammond
Elias Jabbour
Gautam Borthakur
Guillermo Garcia-Manero
Michael Andreeff
Naval Daver
Tapan Kadia
Marina Konopleva
Courtney DiNardo
Farhad Ravandi

Publication Date

12-1-2022

Journal

Leukemia & Lymphoma

Abstract

Deletions in chromosome 7 (del(7)) or its long arm (del(7q)) constitute the most common adverse cytogenetic events in acute myeloid leukemia (AML). We retrospectively analyzed 243 treatment-naive patients with AML and del(7) (168/243; 69%) or del(7q) (75/243; 31%) who did not receive any myeloid-directed therapy prior to AML diagnosis. This is the largest comprehensive clinical and molecular analysis of AML patients with del(7) and del(7q). Our results show that relapse-free survival was significantly longer for AML patients with del(7q) compared to del(7), but the overall survival and remission duration were similar. TP53 mutations and del5/5q were the most frequent co-occurring mutations and cytogenetic abnormalities, and conferred worse outcomes in del(7) and del(7q) patients. Venetoclax-based treatments were associated with worse outcomes in TP53 mutated AML patients with del(7) or del(7q), as well as del(7) with TP53 wildtype status, requiring further investigation.

Keywords

Humans, Chromosomes, Human, Pair 7, Retrospective Studies, Leukemia, Myeloid, Acute, Chromosome Aberrations, Chromosome Deletion, Tumor Suppressor Protein p53

Comments

Supplementary Materials

PMID: 36089905